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A B S T R A C T
The prognostic impact of human papillomavirus (HPV) type on invasive cervical cancer (ICC) was analyzed for
137 women treated for ICC at a single institution between 1999 and 2007. The study subjects were divided into
three groups according to HPV genotype: HPV16-positive (n=59), HPV18-positive (n=33), and HPV16/18-
negative ICC (non-HPV16/18, n= 45). The median follow-up time was 102.5 months (range, 5–179). The 10-
year overall survival (10y-OS) rates in women with FIGO stage I/II disease were similar among HPV genotypes:
94.7% for HPV16 (n= 39), 95.2% for HPV18 (n= 26), and 96.4% for non-HPV16/18 (n= 29). However, the
10y-OS rates in women with FIGO stage III/IV tumors were 73.7% for HPV16 (n= 20), 45.7% for HPV18
(n=7), and 35.7% for other types (n= 16), with significantly higher survival in HPV16-positive compared with
HPV16-negative ICC (10y-OS; 73.7% vs. 39.5%, P= 0.04). This difference in FIGO stage III/IV tumors remained
significant after adjusting for age and histology (hazard ratio 0.30, 95% confidence interval 0.09–0.86,
P=0.02). These results suggest that detection of HPV16 DNA may be associated with a favorable prognosis in
patients with FIGO stage III/IV ICC. Given that most women with FIGO stage III/IV tumors received concurrent
chemoradiotherapy, this finding may imply that HPV16-positive tumors are more chemoradiosensitive.
1. Introduction
Infection with a high-risk human papillomavirus (HPV) is an es-
tablished major risk factor for the development of cervical cancer [1].
HPV16 is the most common genotype detected in invasive cervical
cancer (ICC) worldwide, followed by HPV18, while the 3rd and 4th
most common HPV types vary geographically [2]. Eight HPV genotypes
(16, 18, 31, 33, 35, 45, 52, and 58) have been shown to confer higher
risks of progression to cervical cancer and its immediate premalignant
lesions (cervical intraepithelial neoplasia [CIN] grade 3) compared with
other high-risk and low-risk HPV types in Japan [3,4]. Based on these
data, the clinical guidelines issued by the Japan Society of Obstetrics
and Gynecology and the Japan Association of Obstetricians and Gyne-
cologists recommend a CIN-management algorithm that incorporates
HPV genotyping for risk stratification of progression to CIN3 [5].
However, the association between HPV genotype and the prognosis
of ICC remains controversial. Many studies have reported that HPV18-
positive tumors are associated with a poor prognosis [6–11], while
others failed to identify this relationship [12–17]. Some groups
suggested that HPV16-positive and HPV16/18- positive tumors were
associated with better survival in Chinese and British populations, re-
spectively [12,13], while favorable outcomes were reported for HPV58-
positive tumors in one Taiwanese population [14], and for HPV31-po-
sitive tumors in another Taiwanese study [15]. In contrast, other stu-
dies found no associations between HPV genotype and cervical cancer
prognosis in Russian and Korean populations [16,17]. These conflicting
results may be at least partially due to geographical differences in HPV-
type prevalences.
The present study focused on the impact of HPV types on the sur-
vival of Japanese patients with ICC. We previously analyzed short-term
follow-up data from three institutions (median follow-up, 33 months)
and found that HPV18-positive tumors were associated with poor sur-
vival [8]. In the current study, we analyzed long-term follow-up data
for a different ICC cohort from a single hospital (median follow-up, 102
months). The results suggested that HPV16-positive tumors may be
associated with favorable survival, compared with poorer survival of
patients with HPV18-positive tumors.
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2. Methods
2.1. Study design
We previously analyzed HPV DNA data for 2282 Japanese women
(1517 normal cytology, 318 CIN grade 1, 307 CIN2–3, and 140 ICC)
who visited the University of Tsukuba Hospital or Ibaraki Seinan
Medical Center Hospital for screening or treatment of cervical diseases
between 1999 and 2007 [2]. The present study focused on the prog-
nostic impact of HPV types on ICC, based on the follow-up data for
patients with ICC. Three patients with ICC were treated or followed up
at other hospitals, and we therefore analyzed the clinical data for 137
patients who were treated and followed up for ICC at the University of
Tsukuba Hospital. Written informed consent was obtained from all
patients. The institute ethical and research review board approved the
study protocol.
2.2. HPV genotyping
HPV DNA genotyping was carried out by PCR-based assay, as de-
scribed previously [18]. In brief, exfoliated cells from the ectocervix
and endocervix were collected in a tube containing 1ml of PBS and
stored at −30 °C until DNA extraction. Total cellular DNA was ex-
tracted from cervical samples by a standard SDS-proteinase K proce-
dure. HPV DNA was amplified by PCR using consensus-primers (L1C1/
L1C2+ L1C2M) for the HPV L1 region. A reaction mixture without
template DNA was included in every set of PCR runs as a negative
control. Primers for a fragment of the β-actin gene were used as a
control to rule out false-negative results in samples with no detectable
HPV DNA. HPV types were identified by restriction fragment length
polymorphism (RFLP), which has been shown to identify at least 26
types of genital HPVs [18].
2.3. Statistical analysis
With the sample size of 137 patients, the present study had> 80%
statistical power to detect a relative reduction of 20% in the rate of
death in women with HPV16-positive ICC as compared with those with
HPV16-negative ICC, assuming a 10-year overall survival rate of 70% in
the HPV16-negative group, with the use of a two-sided test at an alpha
level of 0.05.
Associations between HPV genotypes and clinicopathologic data
were evaluated using χ2 or Fisher's exact probability tests as appro-
priate. Continuous variables were analyzed by Student's t-tests. HPV
genotype-specific prognoses among women with ICC were estimated
using the Kaplan-Meier method and compared with log-rank tests.
Because we aimed to calculate cervical cancer-specific survival, patients
who died from other diseases were censored as of the date of death.
Statistical adjustments were made using the Cox regression model. Age
at diagnosis, FIGO stage, histology, and HPV genotype were included in
the multivariate model. All analyses were carried out using the JMP®
10.0 statistics packages (SAS Institute Inc., Cary, NC, USA). Two-sided P
values were calculated throughout and values< 0.05 were considered
to be significant.
3. Results
The clinicopathological characteristics of the patients in this study
are summarized in Table 1. Tumors were classified as FIGO stage I in 68
patients (49.6%), stage II in 26 patients (19.0%), stage III in 38 patients
(27.7%), and stage IV in five patients (3.7%). Histologic analysis in-
dicated 121 tumors (88.3%) as squamous cell carcinoma (SCC) and 16
(11.7%) as adenocarcinoma (AC), including two cases of adenosqua-
mous carcinoma and one case of clear cell carcinoma. Most stage I/II
patients (86%) underwent surgery (with or without adjuvant therapy),
while most stage III/IV patients (97.6%) received radiotherapy alone or
concurrent chemoradiation therapy (CCRT). The median follow-up
period was 102.5 months (range, 5–179).
Based on HPV genotyping results, the study subjects were divided
into three groups: HPV16-positive (n= 59, 43.1%), HPV18-positive
(n= 33, 24.1%), and HPV16/18-negative (non-HPV16/18; n= 45,
32.8%). Patients positive for other types in addition to HPV16 or
HPV18 were classified into the HPV16- or HPV18-positive group, re-
spectively. No patients were positive for both HPV16 and HPV18. The
non-HPV16/18 group included nine HPV-negative patients and 36 pa-
tients with the following genotypes: HPV31 (n=2), HPV33 (n=5),
HPV39 (n=2), HPV51 (n= 1), HPV52 (n=12), HPV 53 (n=2),
HPV58 (n= 5), HPV68 (n= 1), and undetermined types (n=6). The
mean age of the HPV16/18-positive groups was significantly younger
than that of the non-HPV16/18 group (47.2 vs. 53.1 years, P= 0.02), in
keeping with our previous study [8]. There was no significant corre-
lation between HPV genotype and FIGO stage. There was a higher
proportion of AC in the HPV18-positive compared with the HPV18-
negative group (17.7% vs. 9.4%), but the difference was not significant
(P= 0.21).
Univariate analysis including tumors of all stages did not identify
HPV16 positivity as a significant prognostic factor (Table 2). However,
multivariate analysis adjusting for age at diagnosis, FIGO stage, and
histology suggested that women with HPV16-positive ICC were likely to
have a better prognosis. The difference was marginally significant
(hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.15–1.04,
P= 0.06).
Treatment modalities differed between early- and late-stage tumors,
and we therefore also analyzed survival data for FIGO stage I/II and III/
IV tumors separately. The 10-year overall survival (10y-OS) rates were
similar among the three groups in women with FIGO stage I/II disease:
94.7% for HPV16, 95.2% for HPV18, and 96.4% for non-HPV16/18
(Fig. 1A). There was also no difference in survival among FIGO stage I/
II patients who received adjuvant radiation therapy for high-risk of
recurrence (data not shown). However, the 10y-OS rates were 73.7%
for HPV16 (n=20), 45.7% for HPV18 (n= 7), and 35.7% for non-
HPV16/18 (n=16) in women with FIGO stage III/IV tumors (Fig. 1B),
with a significant difference between HPV16-positive and HPV16-ne-
gative ICC (10y-OS; 73.7% vs. 39.5%, P=0.04) (Fig. 1C). This differ-
ence remained significant even after adjusting for age at diagnosis and
histology (HR 0.30, 95%CI 0.09–0.86, P=0.02), demonstrating that
the risk of death was reduced by 70% in patients with HPV16-positive
tumors. When the analysis was confined to patients with SCC, the
survival of patients with FIGO stage III/IV HPV16-positive cervical SCC
was significantly better than that of patients with HPV16-negative tu-
mors (10y-OS; 73.7% vs. 40.7%, P= 0.04). However, we could not
perform a sub-analysis for AC because of the small sample size.
We also analyzed survival data by papillomavirus genus species.
HPV31, 33, 35, 52 and 58 are phylogenetically related to HPV16, and
therefore these types are classified into α9 species [19]. Similarly,
HPV18, 39, 45, 59 and 68 are classified into α7 species. The 10y-OS
rates were 70.0% for α9 species (n=30) and 48.6% for α7 species
(n= 9) in women with FIGO stage III/IV tumors, but the difference was
not statistically significant (P= 0.44).
4. Discussion
Our results suggested that HPV16 positivity may be a favorable
prognostic factor in patients with FIGO stage III/IV ICC. These findings
were consistent with previous studies reporting poor survival associated
with HPV18-positive tumors, in that patients with HPV18-positive tu-
mors had a poorer prognosis than patients with HPV16-positive tumors
[6–11]. Unlike these earlier studies, however, tumors positive for other
HPV types (HPV31, HPV33, HPV52, HPV58 etc.) had similar prognoses
to HPV18-positive tumors, thus suggesting that HPV16-positivity was
associated with overall favorable survival. A recent study also reported
a favorable prognosis in Chinese patients with HPV16-positive tumors
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[12]. Apparently conflicting results regarding the survival of patients
with HPV16/18-negative tumors may be due to misclassification of
HPV genotypes in earlier studies, or geographical differences in HPV-
type prevalences.
The current study showed stage-specific results, with the favorable
survival effect of HPV16 positivity restricted to FIGO stage III/IV tu-
mors. However, several studies have reported significant associations
between HPV18 detection and poor prognosis in early-stage ICC
[6,7,11], suggesting rapid spread of HPV18-positive tumors during the
early stage. Given that few patients with FIGO stage I/II tumors died
from the disease in the present study, our sample size may have been
too small to detect any slight differences in survival among early-stage
tumors with different HPV genotypes.
Most patients with FIGO stage III/IV disease received radiotherapy,
and our findings thus suggested that HPV16-positive tumors may dis-
play greater radiosensitivity. Moreover, most of these cases received
CCRT, also implying that HPV16 was associated with greater
chemoradiosensitivity. Using an in vitro radiosensitivity assay for cer-
vical tumors and cell lines, a recent study suggested that intrinsic
radiosensitivity of cervical tumors may not vary by HPV genotype [20].
Another recent study reported that HPV genotype may affect risks of
distant metastases after radiotherapy, but not risks of local recurrences
in the radiation field [21]. Therefore, HPV genotype may be associated
with chemosensitivity or chemoradiosensitivity of cervical tumors.
Early studies employed radiation therapy alone for FIGO III/IV tumors
[7–9,14], while recent studies have mainly used CCRT [12,13] since
five randomized trials comparing CCRT with radiation alone showed
that CCRT was associated with a significant reduction in recurrence and
death [22]. Conflicting results regarding the associations between HPV
type and survival may reflect this difference in radiotherapy, and recent
studies reporting better survival in HPV16-positive or HPV16/18-po-
sitive tumors used CCRT for FIGO stage III/IV tumors [12,13].
The favorable survival effect of HPV16 positivity may be limited to
SCC, and two studies to date have reported no impact of HPV type on
survival in patients with AC [23,24]. In our earlier study, patients with
HPV16-positive AC showed similar survival to those with HPV18-po-
sitive SCC and AC [8]. Unfortunately, we could not evaluate the asso-
ciation between HPV type and AC survival in the present study because
most FIGO stage III/IV tumors showed SCC histology.
In the present study, other prognostic factors such as tumor size,
lymph node status, and histological grade were not included in the
multivariate analyses, and HPV genotype may therefore not be an in-
dependent prognostic factor in ICC. However, the results suggest that
HPV genotype may still serve as a prognostic biomarker, if not ne-
cessarily an independent one, representing many prognostic factors or
predicting radiation effects.
Several studies suggested that tumors positive for HPV α9 species
(including HPV16) are associated with a better prognosis [20,21,25].
Our results were consistent with these studies, but the association did
not reach statistical significance because tumors positive for HPV16-
related types (HPV31, 33, 52 and 58) had similar prognoses to HPV18-
positive tumors. To address whether species grouping is more useful for
predicting prognosis of cervical cancer patients, large-scaled studies
will be warranted.
The mechanisms whereby HPV genotypes affect the survival of
Table 1
Characteristics of the study subjects according to HPV genotype.
All HPV genotype
HPV16 HPV18 Non-HPV16/18
(n=137) (n= 59) (n= 33) (n= 45)
Age
Mean± SD (year) 49.2 ± 14.8 49.0 ± 14.1 44.1 ± 14.9 53.1 ± 14.8
< 50 80 35 23 22
≧ 50 57 24 10 23
FIGO stage
I 68 27 22 19
II 26 12 4 10
III 38 18 7 13
IV 5 2 0 3
Histology
SCC 121 53 27 41
Non-SCC 16 6 6 4
Treatment by FIGO stage
Stage I/II 94 39 26 29
Surgery± adjuvant therapy 83 34 24 25
CCRT 7 3 1 3
Radiotherapy alone 4 2 1 1
Stage III/IV 43 20 7 16
CCRT 35 16 6 13
Radiotherapy alone 6 3 1 2
Chemotherapy alone 2 1 0 1
Abbreviations: HPV, human papillomavirus; SD, standard deviation; FIGO, The International Federation of Gynecology and Obstetrics; SCC, squamous cell carci-
noma, CCRT, concurrent chemoradiation therapy.
Table 2
Univariate and multivariate analyses of prognostic factors for overall survival in
patients with invasive cervical cancer.
n Univariate analysis Multivariate analysis
10y-OS P value Hazard Ratio (95%CI) P value
Age
< 50 80 0.84 0.85 2.52 (1.01–6.46) 0.048
≧ 50 57 0.82 1
FIGO stage
III/IV 43 0.57 < 0.0001 18.9 (6.50–68.7) < 0.0001
I/II 94 0.95 1
Histology
Non-SCC 16 0.86 0.68 0.95 (0.15–3.51) 0.95
SCC 121 0.83 1
HPV16 DNA
Positive 59 0.88 0.30 0.42 (0.15− 1.04) 0.06
Negative 78 0.80 1
Abbreviations: HPV, human papillomavirus; FIGO, The International
Federation of Gynecology and Obstetrics; SCC, squamous cell carcinoma; 10y-
OS, 10 year-overall survival; 95%CI, 95% confidence interval.
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cervical cancer patients remain unknown. HPV16 and HPV18 are
commonly associated with SCC and AC, respectively [2]. In addition,
intra-type variant sequences related to HPV16-positive AC and HPV18-
positive SCC have also been reported [26,27]. It is therefore likely that
differences in HPV genome sequences may determine the biological
characterization, as well as the histology, of cervical cancer cells. Re-
cent studies have suggested that hot spots of HPV integration may be
type-specific, and may determine the histology and biological char-
acterization of ICC [28,29].
The main limitation of the present study was its small number of
subjects. As noted above, we were unable to evaluate the impact of
HPV16 on survival in patients with early-stage tumors or ACs because
of this limitation. In addition, the present study was based on retro-
spective data analysis and not originally planned to evaluate the
prognostic impact of HPV genotypes on ICC. The present study may not
be able to draw definitive conclusions because of these limitations. To
confirm our findings, a larger-scaled prospective study is now in pro-
gress in Japan.
In conclusion, the results of this study suggest that HPV16 positivity
may be a favorable prognostic factor in patients with FIGO stage III/IV
ICC, implying that HPV16 positivity may be associated with greater
chemoradiosensitivity. A better understanding of the mechanisms un-
derlying the association between HPV genotype and survival may lead
to the development of new treatment approaches for patients with
cervical cancer.
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